Polymorphs of the hydrochloride salt of linaprazan glurate

US11820772B2 · kind B2 · utility

Assignee

• Cinclus Pharma Holding AB (Publ) · SE

Inventors

• Kjell Jarring · Lund, SE
• Thomas Larsson · Luleå, SE
• Xingbang Lin · Longbeilingcun, CN
• Dan Wang · Fremont, US
• Mikael Hillgren · Örebro, SE

Key dates

• Filing date: Apr 3, 2023
• Grant date: Nov 21, 2023
• Expiry date: Apr 3, 2043

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07B2200/13
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

The present invention relates to polymorphs of the hydrochloride salt of 5-{2-[({8-[(2,6-dimethylbenzyl)amino]-2,3-dimethylimidazo[1,2-a]pyridine-6-yl}carbonyl)-amino]ethoxy}-5-oxopentanoic acid (linaprazan glurate), more specifically Form 1 and Form 2 of the HCl salt of linaprazan glurate. The invention also relates to a process for the preparation of such polymorphs, to pharmaceutical compositions comprising such polymorphs, and to the use of these polymorphs in the treatment or prevention of gastrointestinal inflammatory diseases or gastric acid related diseases, in particular erosive gastroesophageal reflux disease (eGERD).